Printer Friendly

COMPANY INFORMATION
Lorus Therapeutics Inc. 2 Meridian Rd Toronto, ON M9W 4Z7 Tel: (416) 798-1200 Fax: (416) 798-2200 Contact Name Grase Tse Industry Biotechnology		Key Executives Aiping H. Young, CEO Elizabeth Williams, acting CFO Researches, develops and commercializes pharmaceutical products and technologies for the treatment of cancer. The company's lead product candidates include LOR-2040 (Phase II), an antisense therapeutic drug for the treatment of various cancers; and LOR-253 (Preclinical), an anti-cancer small molecule drug.
FP ADVISOR COVERAGE Lorus Therapeutics Inc. • FP Corporate Analyzer • FP Directory of Directors • FP Corporate Surveys • Ordering FP Products		TOP INDUSTRY PLAYERS Biotechnology Company Name Revenue ($000s)  Atrium Innovations Inc. 309,546 Angiotech Pharmaceuticals, Inc. 302,251 QLT Inc. 132,457 Oncothyreon Inc. 42,678 AEterna Zentaris Inc. 41,056 (Links are to Snapshots.)
FINANCIAL RATIOS AS OF FEB 8/10 Listed Close 52-wk High 52-wk Low IAD Latest Dividend Yield 60-mo Beta TSX/LOR $0.07 $0.10 $0.03 n.a. n.a. n.a. n.a. Avg 20-day Volume P/E 12-mo EPS EPS Date 1-yr Return 3-yr Return 5-yr Return Market Cap. (000s) 71,516 6.50 $0.01 Nov. 30/09 44.44% n.a. n.a. $19,371
ANNUAL FINANCIALS Periods ended: 12m May 31/09 12m May 31/081 12m May 31/07 $000s $000s $000s Operating revenue 184 43 107 Net income (8,860) (6,334) (9,638) Total assets 7,527 11,607 15,475 $ $ $ Earnings per share* (0.04) (0.03) (0.05)   * Common 1 Results prior to July 10, 2007, pertain to (old) Lorus Therapeutics Inc. (renamed Global Summit Real Estate Inc.)
TRAILING 12-MONTH VALUES Periods ended: Nov. 30/09 Nov. 30/08 $000s $000s Operating revenue 270 58 Net income (9,800) (11,996) $ $ Earnings per share (0.05) (0.06)

COMPANY NEWS

Results for 'Lorus Therapeutics Inc.' from past 30 days: No hits. (Links are to articles.)